19th Jun 2006 11:00
Vernalis PLC19 June 2006 June 19, 2006 Vernalis plc to Present at Investor Conferences during June 2006 WINNERSH, U.K., June 19, 2006 -- Vernalis plc (LSE: VER, Nasdaq: VNLS), aspecialty bio-pharmaceutical and drug development company, today announced thatSimon Sturge, Chief Executive Officer, and Tony Weir, Chief Financial Officer,will participate in select investor conferences during the month of June.Vernalis will present an overview of its business activities and productpipeline and will be conducting one-on-one meetings with investors. Piper Jaffray Health Care Conference will be held June 22-23, 2006 at TheBrewery in London. Vernalis is scheduled to present at 10:20 AM BST on Thursday,June 22, 2006. Jefferies Life Sciences Conference will be held June 27-28, 2006 at the MandarinOriental in New York City. Vernalis is scheduled to present at 9:30 AM Easterntime on Wednesday, June 28, 2006. To listen to the audio webcast of thepresentation, please visit: http://www.wsw.com/webcast/jeff11/vnls/ About VernalisVernalis is a speciality bio-pharmaceutical company focused on products marketedto specialist neurologists. The company has two marketed products, Frova(R) andApokyn(R), and a development pipeline focused on neurology and central nervoussystem disorders. The company has seven products in clinical development andcollaborations with leading, global pharmaceutical companies including Novartis,Biogen Idec and Serono. Vernalis has established a US commercial operation topromote Apokyn(R) and co-promote Frova(R) alongside its North American licensingpartner, Endo Pharmaceuticals, propelling the company towards its goal ofbecoming a sustainable, self-funding, R&D-driven, speciality bio-pharmaceuticalcompany. For further information about Vernalis, please visit www.vernalis.com. -- ends -- Enquiries: Vernalis plc +44 (0) 118 977 3133 Simon Sturge, Chief Executive OfficerTony Weir, Chief Financial OfficerJulia Wilson, Head of Corporate Communications Vernalis Forward-Looking Statement This news release may contain forward-looking statements that reflect theCompany's current expectations regarding future events including the clinicaldevelopment and regulatory clearance of the Company's products and includingthat of Frova(R) for menstrual migraine, the Company's ability to find partnersfor the development and commercialisation of its products, the benefits ofre-acquiring Frova(R) in North America and the partnership with Endo on theCompany's liquidity and results of operations, as well as the Company's futurecapital raising activities. Forward-looking statements involve risks anduncertainties. Actual events could differ materially from those projected hereinand depend on a number of factors including the success of the Company'sresearch strategies, the applicability of the discoveries made therein, thesuccessful and timely completion of clinical studies, including with respect toFrova(R) and the Company's other products, the uncertainties related to theregulatory process, the ability of the Company to identify and agree beneficialterms with suitable partners for the commercialisation and/or development ofFrova(R) and other products, as well as the achievement of expected synergiesfrom such transactions, the acceptance of Frova(R) and other products byconsumers and medical professionals, the successful integration of completedmergers and acquisitions and achievement of expected synergies from suchtransactions, and the ability of the Company to identify and consummate suitablestrategic and business combination transactions. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Vernalis PLC